Sabrina H Rossi, Jessica Kitt, Angela Godoy, Fiona Farquhar, Jon Cartledge, Michael Kimuli, Hannah Bailey, Simon Burbidge, Neil Hancock, Catriona Marshall, Suzanne Rogerson, Matthew E J Callister, Juliet A Usher-Smith, Grant D Stewart
{"title":"Prevalence of Kidney Cancer in Attendees for Combined Lung and Kidney Cancer Screening by Computed Tomography Scanning.","authors":"Sabrina H Rossi, Jessica Kitt, Angela Godoy, Fiona Farquhar, Jon Cartledge, Michael Kimuli, Hannah Bailey, Simon Burbidge, Neil Hancock, Catriona Marshall, Suzanne Rogerson, Matthew E J Callister, Juliet A Usher-Smith, Grant D Stewart","doi":"10.1016/j.euo.2025.07.004","DOIUrl":null,"url":null,"abstract":"<p><p>Kidney cancer (KC) screening may be facilitated by targeting individuals at a higher risk and combining with other screening programmes. Previous estimates of the prevalence of screen-detected KC are outdated and do not enable an accurate assessment in a high-risk group. The Yorkshire Kidney Screening Trial (YKST) is a unique study of the feasibility of adding KC screening via an abdominal noncontrast computed tomography (CT) scan to the thoracic low-dose CT within a targeted lung cancer screening trial in ever smokers (Yorkshire Lung Screening Trial; YLST). Seventeen histologically confirmed KC cases were detected on thoracic CT in YLST (N = 6650; prevalence 0.26%; 95% confidence interval [CI] 0.15-0.41%), which has implications for future service planning to accommodate the investigation and treatment of screen-detected KC patients following the national adoption of lung cancer screening. Adding abdominal CT in YKST (n = 4019) identified an additional ten histologically confirmed KC patients (prevalence 0.25%; 95% CI 0.12-0.46%). In summary, using data from YKST, we report the first contemporary estimates of the prevalence of KC in high-risk individuals, key data required to plan future prospective screening studies.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":9.3000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2025.07.004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Kidney cancer (KC) screening may be facilitated by targeting individuals at a higher risk and combining with other screening programmes. Previous estimates of the prevalence of screen-detected KC are outdated and do not enable an accurate assessment in a high-risk group. The Yorkshire Kidney Screening Trial (YKST) is a unique study of the feasibility of adding KC screening via an abdominal noncontrast computed tomography (CT) scan to the thoracic low-dose CT within a targeted lung cancer screening trial in ever smokers (Yorkshire Lung Screening Trial; YLST). Seventeen histologically confirmed KC cases were detected on thoracic CT in YLST (N = 6650; prevalence 0.26%; 95% confidence interval [CI] 0.15-0.41%), which has implications for future service planning to accommodate the investigation and treatment of screen-detected KC patients following the national adoption of lung cancer screening. Adding abdominal CT in YKST (n = 4019) identified an additional ten histologically confirmed KC patients (prevalence 0.25%; 95% CI 0.12-0.46%). In summary, using data from YKST, we report the first contemporary estimates of the prevalence of KC in high-risk individuals, key data required to plan future prospective screening studies.
期刊介绍:
Journal Name: European Urology Oncology
Affiliation: Official Journal of the European Association of Urology
Focus:
First official publication of the EAU fully devoted to the study of genitourinary malignancies
Aims to deliver high-quality research
Content:
Includes original articles, opinion piece editorials, and invited reviews
Covers clinical, basic, and translational research
Publication Frequency: Six times a year in electronic format